Scientist, Vaccine R&D
CurrentDesigned and constructed a plasmid template for in-vitro transcription of mRNA vaccines. Included literature research, using sequence editing software such as DNA Star and Snap Gene, primer design, writing protocols, and executing multiple experiments using Gibson assembly, colony PCR, Maxi Prep, DNA extraction/purification, gel electrophoresis, restriction digest, and sequencing. Developed methods to generate and purify mRNA vaccines from a plasmid template, which involved literature research, writing protocols, in-vitro transcription, DNA purification, and RNA purification via oligo dT chromatography on an AKTA Avant liquid chromatography system. Designed and optimized a process to generate a CHIKV-Luciferase reporter virus from a plasmid template. Involved restriction digests, agarose and formaldehyde gel electrophoresis, in-vitro transcription, spin-column purification, phenol:chloroform extraction, and RNA electroporation. Also included BSL-2 level virus work including virus expansions, plaque assays, and CHIKV neutralization assays to characterize newly generated lots of CHIKV-Luciferase virus. Generated and qualified a GxP lot of virus to be used in phase III virus neutralization assays. Developed a process to sequence the RNA genome of a recombinant CHIKV-Luciferase reporter virus, which involved viral RNA extraction, RT-PCR, PCR, gel extraction, primer design, sequence assembly, and analysis. Characterized recombinant Adenovirus vaccine candidates for HIV by PCR, qPCR, Western blot, sequencing, restriction digest/gel electrophoresis, and viral growth curves. Developed and performed cell-based neutralization assays to determine the NT80 titer of neutralizing antibodies in human serum samples for phase II and phase III clinical trials of a Chikungunya (CHIKV) VLP vaccine candidate. Developed human and NHP ELISAs to determine the titer of CHIKV reactive IgG and IgM antibodies.